THE ROLE OF MAP KINASE PATHWAY ACTIVATION IN THE TREATMENT OF NRAS-MUTANT AND THERAPY-RESISTANT BRAF-MUTANT MELANOMA
$311,862FY2022Defense Health AgencyDOD
The Broad Institute, Inc
Investigators
View source on USAspending →THE ROLE OF MAP KINASE PATHWAY ACTIVATION IN THE TREATMENT OF NRAS-MUTANT AND THERAPY-RESISTANT BRAF-MUTANT MELANOMA · GrantIndex